Cite
HARVARD Citation
Rocconi, R. et al. (2021). Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL). Obstetrical & gynecological survey. 76 (3), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Rocconi, R. et al. (2021). Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL). Obstetrical & gynecological survey. 76 (3), p. . [Online].